What if you'd held CRVS?
A $1,000 investment in Corvus Pharmaceuticals, Inc. (CRVS) at the month-end close of 2016-03 would be worth $1,062 at the close of 2026-08 — +6.2% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $3,742.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2016
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2016 | $1,000 | — |
| 2017 | $724 | -27.6% |
| 2018 | $257 | -64.6% |
| 2019 | $380 | +48.2% |
| 2020 | $249 | -34.6% |
| 2021 | $169 | -32.3% |
| 2022 | $59.44 | -64.7% |
| 2023 | $123 | +107.1% |
| 2024 | $374 | +204.0% |
| 2025 | $538 | +43.9% |
| 2026 | $1,077 | +100.0% |
Best and worst month-end to buy
The best single month-end close to have bought CRVS was 2023-02 ($0.73): $1,000 then is $21,096 today. The worst was 2017-03 ($20.77): $1,000 then is $741.
FAQ
What would $1,000 in CRVS be worth today?
A $1,000 investment in Corvus Pharmaceuticals, Inc. (CRVS) at the start of 2016 would be worth about $1,062 today, a total return of +6.2%. Dividends are reinvested in these figures.
What were the best and worst years for CRVS?
Corvus Pharmaceuticals, Inc. (CRVS)'s strongest calendar year since 2016 was 2024, a +204.0% return — $1,000 held through that year became about $3,040 by year-end. Its weakest year was 2022, at -64.7%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in CRVS have grown?
Investing $100 at the end of every month since 2016-03 would have grown to about $64,056 on $12,600 invested.
Did CRVS beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $3,742. CRVS trailed the S&P 500 by +71.6% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Corvus Pharmaceuticals, Inc. (CRVS) historical total-return data from 2016-03 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.